Press releases
Proceeds will advance STORM’s potential first-in-class clinical program targeting METTL3 for treatment of solid tumors and leukemias. Financing will further expand STORM’s novel discovery platform to create additional products targeting RNA modification.
Read more
STC-15 is the first molecule specifically targeting an RNA methyltransferase to enter clinical development
Read more
STC-15 is an oral small molecule inhibitor of the RNA methyltransferase METTL3. STORM’s first-in-class lead program to enter clinical development in solid tumors in 2022.
Read more
STORM recognised as an innovative early-stage biotechnology company pioneering novel drug targets
Read more
Industry veteran to lead STORM as it transitions into a clinical-stage company with a pipeline of products targeting RNA modifying enzymes
Read more